Hartmut Döhner

发表

Martin A. Nowak, Eric S. Lander, Kristian Cibulskis, 2015 .

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Michael Hallek, Olga Samoylova, Elina Asikanius, 2014, The New England journal of medicine.

Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma

Stephan Wolf, Peter Lichter, Thomas Boehm, 1998, Oncogene.

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

Claudio Lottaz, Stefan Fröhling, Jonathan R Pollack, 2007 .

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Manuela Zucknick, Verena I Gaidzik, Lars Bullinger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Axel Benner, Stefan Fröhling, Lars Bullinger, 2008, The New England journal of medicine.

Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization.

Stefan Fröhling, Bernhard Radlwimmer, Peter Lichter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.

Lars Bullinger, Hartmut Döhner, Konstanze Döhner, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Chromosome 7: DNA Sequence and Biology

Junjun Zhang, Nazneen Rahman, Alexander K. Hudek, 2003, Science.

Acute Myeloid Leukemia.

Daniel J Weisdorf, Hartmut Döhner, C. Bloomfield, 2015, The New England journal of medicine.

Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice.

Axel Benner, Peter Lichter, Lars Bullinger, 2002, Blood.

Precision oncology for acute myeloid leukemia using a knowledge bank approach

Inigo Martincorena, Verena I Gaidzik, Peter J Campbell, 2017, Nature Genetics.

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Hisashi Sakamaki, Hartmut Döhner, Richard Schlenk, 2009, JAMA.

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.

Robert Tibshirani, Stefan Fröhling, Jonathan R Pollack, 2008, Blood.

Circulating microRNAs in hematological diseases: principles, challenges, and perspectives.

Christian Langer, Christian Buske, Hartmut Döhner, 2013, Blood.

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

Lars Bullinger, Christian Buske, Wolfgang Hiddemann, 2012, Blood.

Mutations driving CLL and their evolution in progression and relapse

Martin A. Nowak, Eric S. Lander, Kristian Cibulskis, 2015, Nature.

First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine

Thomas Kull, Felix M Mottaghy, Gerhard Glatting, 2008, Journal of Nuclear Medicine.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Axel Benner, Stefan Fröhling, Hartmut Döhner, 2002, Blood.

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.

Axel Benner, Peter Lichter, Dirk Winkler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Axel Benner, Dirk Winkler, Jennifer Edelmann, 2008, Blood.

Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.

Michael Heuser, Lars Bullinger, Brigitte Schlegelberger, 2005, Haematologica.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Bob Löwenberg, Benjamin L Ebert, Pierre Fenaux, 2017, Blood.

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

Guido Marcucci, Manuela Zucknick, Lianbo Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Dirk Winkler, Hartmut Döhner, Stephan Stilgenbauer, 2008, Blood.

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization

Thomas Cremer, Michael R. Speicher, Stefan Joos, 1993, Human Genetics.

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

Axel Benner, Peter Lichter, Lars Bullinger, 2007, Haematologica.

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Torsten Haferlach, Guido Marcucci, Hartmut Döhner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Verena I Gaidzik, Lars Bullinger, Hartmut Döhner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Verena I Gaidzik, Michael Heuser, Lars Bullinger, 2019, Nature Communications.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

Donna Neuberg, Benjamin L. Ebert, Scott A. Armstrong, 2019, Science.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Randy Allred, Hubert Serve, Wolfgang E Berdel, 2005, Blood.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Stefan Fröhling, Lars Bullinger, Claudia Scholl, 2005, Blood.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia

Lars Bullinger, Hans A Kestler, Hartmut Döhner, 2011, Haematologica.

From Pathogenesis to Treatment of Chronic Lymphocytic

Hartmut Döhner, Stephan Stilgenbauer, Ralf Küppers, 2010 .

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Michael Hallek, Emili Montserrat, Bruce D Cheson, 2008, Blood.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Michael Heuser, Daniela Weber, Hartmut Döhner, 2015, British journal of haematology.

Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway

Axel Benner, Hartmut Döhner, Stephan Stilgenbauer, 2008, Cell cycle.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Stefan Fröhling, Benjamin L Ebert, Todd R Golub, 2007, Cancer cell.

Minimal sizes of deletions detected by comparative genomic hybridization

Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer, 1998, Genes, chromosomes & cancer.

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Michael Hallek, Dirk Winkler, Raymonde Busch, 2009, Blood.

Clonal Evolution in Chronic Lymphocytic Leukemia: Acquisition of High-Risk Genomic Aberrations Associated with Unmutated VH, Resistance to Therapy, and Short Survival.

Axel Benner, Peter Lichter, Lars Bullinger, 2006 .

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Paola Fazi, Marco Vignetti, Giuseppe Avvisati, 2013, The New England journal of medicine.

Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations.

Gunnar Wrobel, Bernhard Radlwimmer, Peter Lichter, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Acute myeloid leukaemia

Hartmut Döhner, E. Estey, H. Döhner, 2006, The Lancet.

Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications

Hartmut Döhner, Stephan Stilgenbauer, H. Döhner, 2008, Leukemia & lymphoma.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.

t(11;14)‐positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B‐cell chronic lymphocytic leukemia

Michael Baudis, Peter Lichter, Peter Möller, 2000, Genes, chromosomes & cancer.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of several leukemia‐associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

Hartmut Döhner, H. Döhner, M. Schmitt, 2003, International journal of cancer.